摘要
探讨乙型肝炎病毒（ＨＢＶ）前Ｃ区突变株（１８９６位点Ｇ→Ａ点突变）慢性感染患者的临床特点、病理特征及与干扰素疗效的关系。方法采用突变特异性ＰＣＲ检测１０８份慢性ＨＢＶ感染患者血清和／或肝组织中ＨＢＶ前Ｃ区突变株，按Ｋｎｏｄｅｌｌ方法评价肝组织病理损伤。结累ＨＢＶ前Ｃ区突变株在不同ｅ系统均存在，但ＨＢｅＡｂ（＋）组中单纯突变株感染或突变株感染占优势的混台感染（１４．２９％，４６．２３％）显著地高于ＨＢｅＡｇ（＋）组（０％，６．４５％）；突变株感染与肝脏疾病严重程度相关，慢性肝炎重度组检出率（１３．６４％，４０．９１％）极显著地高于慢性无症状携带者（０％，１０．２６％）。５例前Ｃ区突变株感染者应用干扰素治疗可产生应答和无应答２种结果。临床症状较轻的ＨＢＶ前Ｃ区突变株感染者的肝脏病理损伤程度无明显加重。结论前Ｃ区突变株感染普遍存在，但更常见于ＨＢｅＡｂ阳性者。【关键词】##4乙型肝炎病毒;;突变;;病理学;;
Objective To elucidate the clinical feature, P8thological chage and IFN therapy of HBVpre-c mutant(l 896 G-A Point mutation). Methods Mutation specific PCR was employed for detectingPare mutation from 108 serum and/or liver samples of P8tients with chronic hepatitis B infection. Liverdamage was evaluated with Knodell s histology activity index(HAI) in 46 patients. Results HBV precoremutant existed popularly in different e systems status, but the detective rate of HBV precore mutant ormutant prevailing over wild type in HBeAb+ group(14.29%, 46.23%) was signifcantly higher than that inHbeAg+(0%, 6.45%)grorp Mutant infection was associated with the seventy of liver diseases, the detectiverate in severe chronic hepatitis group was significantly higher(13.64%, 40.91%) than that in chronicaSympotamatic carriers troupe(0%, 15.62%). 5 precore mutant positive patients with IFN treatment showedaether response or nonresponse to IFN therapy. There was no significant difference of liver pathologicalchance between mutant type and wild type infection in patients with mild chronic hepatitis. ConclusionHBV precore mutant infection existed commonly in patients with chronic hepatitis B, despite of the esystem status, though it was more prevalent in patients with HBeAb positive. Further study is needed inthe pathogenicity and the treatment of HBV precore mutation.
出处
《中华肝脏病杂志》
CAS
CSCD
1999年第1期17-19,共3页
Chinese Journal of Hepatology
